A Case of Elexacaftor/Tezacaftor/Ivacaftor–Induced Depressive Symptoms and Suicidal Thoughts

References (6)

1. Heijerman HGM, McKone EF, Downey DG, et al; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomized, phase 3 trial. 2019;394(10212):1940–1948. PubMed CrossRef
2. Spoletini G, Gillgrass L, Pollard K, et al. Dose adjustments of elexacaftor/tezacaftor/ivacaftor in response to mental health side effects in adults with cystic fibrosis. J Cyst Fibros. 2022;21(6):1061–1065. PubMed CrossRef
3. Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. 2014;69(12):1090–1097. PubMed CrossRef
4. McKinzie CJ, Goralski JL, Noah TL, et al. Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis. J Cyst Fibros. 2017;16(4):525–527. PubMed CrossRef
5. Talwalkar JS, Koff JL, Lee HB, et al. Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis. 2017;58(4):343–354. PubMed CrossRef
6. Tindell W, Su A, Oros SM, et al. Trikafta and psychopathology in cystic fibrosis: a case report. 2020;61(6):735–738. PubMed CrossRef